Healthcare costs and resources utilization in children with difficult‐to‐control asthma treated with biologic therapies: A population‐based cohort study

Author:

Monzio Compagnoni Matteo12ORCID,Conflitti Claudia12ORCID,Capuano Veronica34,Bonaiti Giulia4,Franchi Matteo12,Vimercati Chiara5,Biondi Andrea35,Luppi Fabrizio34,Corrao Giovanni12,Faverio Paola34ORCID

Affiliation:

1. National Centre for Healthcare Research & Pharmacoepidemiology University of Milano‐Bicocca Milan Italy

2. Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods University of Milano‐Bicocca Milan Italy

3. School of Medicine and Surgery University of Milano‐Bicocca Monza Italy

4. Respiratory Unit Fondazione IRCCS San Gerardo dei Tintori Monza Italy

5. Pediatrics Fondazione IRCCS San Gerardo dei Tintori Monza Italy

Abstract

AbstractIntroductionAsthma is one of the most common diseases in children, with a variable range of severity. In recent years, treatment for severe asthma has been largely improved by the availability of targeted biologic therapies. Nevertheless, studies reporting real‐world data and cost‐effectiveness analyses are lacking. The aim of this study was to evaluate, on a population‐based cohort of children with asthma, the impact of the treatment with biologics on healthcare service utilization and associated costs.MethodsData were retrieved from Healthcare Utilization database of Lombardy region (Italy). A cohort of 46 asthmatic children aged 6–11 in treatment with dupilumab, mepolizumab or omalizumab was identified during 2017–2021. We compared healthcare resources use between the year before (“baseline period”) and the year after the treatment initiation (“follow‐up period”). Average 1‐year healthcare costs were also calculated.ResultsComparing the baseline with the follow‐up period, the number of patients with at least one exacerbation‐related hospitalization and ER access decreased by 75.0% and 85.7%, respectively. The use of biologic agents, namely omalizumab, mepolizumab and dupilumab, significantly reduced oral corticosteroids (OCS), short‐acting β2‐agonists and the association inhaled corticosteroids/long‐acting β2‐agonists use. ER admissions for non‐respiratory causes were also significantly reduced, while discontinuation rate was low (6.5%). The overall costs increased, due to the costs of the biologic agents, but the hospital admission‐related costs due to respiratory causes reduced significantly.ConclusionsOur real‐world investigation suggests that biologic agents reduced hospital admissions for respiratory causes and use of anti‐asthmatic drugs, including OCS. However, long‐term healthcare sustainability still needs more in‐depth assessments.

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference25 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3